



MAY 16 2000
TECH CENTER 1600/2900

INFORMATION DISCLOSURE CITATION (Use several sheets if necessary)		ATTY. DOCKET NO. PC10487A	SERIAL NO. 09/518408
		APPLICANT Kristin M. Lundy	
		FILING DATE March 3, 2000	GROUP 1614

U.S. PATENT DOCUMENTS

EXAMINER INITIALS	DOCUMENT NUMBER							DATE	NAME	CLASS	SUBCLASS	FILING DATE IF APPROPRIATE
	3	5	3	6	8	0	9	10/27/70	Norman Applezweig	424	28	
	3	5	9	8	1	2	3	08/10/71	Alejandro Zaffaroni	127	424	265
	3	6	3	0	2	0	0	06/09/69	Takeru Higuchi	128	204	268
	3	8	4	7	7	7	0	11/12/74	Sol Radlowe, et al.	424	159	23
	3	9	1	6	8	9	9	11/07/75	Theeuwes, et al.	128	260	
	4	0	0	8	7	1	9	02/22/77	Theeuwes, et al.	128	260	
	4	6	8	7	6	1	0	08/17/87	Vassilatos	264	211	14
	4	7	6	9	0	2	7	09/06/88	Baker, et al.	424	493	
	5	0	5	9	5	9	5	10/22/91	LeGrazie	424	468	
	5	0	7	3	5	4	3	12/17/91	Marshall, et al.	514	21	
	5	1	2	0	5	4	8	06/09/92	McClelland, et al.	424	473	
	5	3	5	4	5	6	6	10/11/94	Addesso, et al.	426	19	
	5	5	3	8	9	8	4	07/23/96	Villalobos, et al.	514	322	
	5	5	9	1	7	6	7	01/07/97	Mohr, et al.	514	413	
5	6	3	9	4	7	6	06/17/97	Oshlack, et al.	424	465		
	5	6	7	4	5	3	3	10/07/97	Santus, et al.	424	452	493
	5	7	3	3	5	6	6	03/31/98	Lewis	424	426	
	5	7	5	0	5	4	2	05/12/98	Villalobos, et al.	514	322	

FOREIGN PATENT DOCUMENTS

	DOCUMENT NUMBER							DATE	COUNTRY	CLASS	SUBCLASS	TRANSLATION		
												YES	NO	
	9	2	1	7	4	7	5	10/15/92	PCT					X

OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages, Etc.)

	Cummings, et al.; β -Amyloid Accumulation Correlates with Cognitive Dysfunction in the Aged Canine; Neurobiology of learning and Memory; Vol. 66, pp 11-23, (1996).
2	Ruehl, et al.; Canine Cognitive Dysfunction; Psychopharmacology of Animal Behavior Disorders; pp 283-304, (1998).

Express Mail No. E162822035US
Date June 28, 2001

MAY 12 2000

INFORMATION DISCLOSURE CITATION LIST. DOCKET NO. PC10487A SERIAL NO. 09/518408

(Use several sheets if necessary)

APPLICANT Kristin M. Lundy

FILING DATE March 3, 2000

GROUP 164

3.	Corey-Bloom, et al.; Monoamine Oxidase Inhibitors in Alzheimer's Disease; Monoamine Oxidase Inhibitors in Neurological Diseases; pp. 279-294 (1994).
4.	Finnegan; Inhibition of Monoamine Oxidase B and the Neuroprotective Effects of Selegiline; Monamine Oxidase Inhibitors in Neurological Diseases; pp. 210-216 (1994).
5.	Hart, et al.; Selecting, Raising, and Caring for Dogs to avoid Problem Aggression; JAVMA, Vol. 210, No. 8; pp 1129-1134 (1997).
6.	Ruehl, et al.; Canine Cognitive Dysfunction as a Model for Human age-related Cognitive Decline, Dementia and Alzheimer's Disease; Progress in Brain Research; Vol. 106: 217-225, (1995).
7.	Ruehl, et al.; Therapeutic Actions of L-Deprenyl in Dogs: A Model of Human Brain Aging; Advances in Pharmacology; Vol. 42: pp 316-319, (1998).
8.	E. Head, et al.; Spatial Learning and Memory as a Function of Age in the Dog; Behavioral Neuroscience; Vol. 109, pp 851-858 (1995).
9.	E. Head, et al.; The Effects of L-Deprenyl on Spatial Short Term Memory in Young and aged Dogs; Prog. Neuro-Psychopharmacol. & Biol. Psychiatry; Vol. 20, pp 515-530, (1996).
10.	Mimori, et al.; Abnormalities of Acetylcholinesterase in Alzheimer's Disease with Special Reference to effect of Acetylcholinesterase Inhibitor; Behav. Brain Res. Vol., 83, pp. 25-30, (1997).
11.	Ellman, et al.; A New and Rapid Colorimetric Determination of Acetylcholinesterase Activity; Biochemical Pharmacology; Vol. 7, pp 88-95 (1960).
EXAMINER	DATE CONSIDERED

EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

Conforms with FORM PTO-FB-A820

INFORMATION DISCLOSURE